Xu Qiang, Yin Bohui, Han Xu, Ren Siqian, Jiang Jialin, Li Fang, Wijarnpreecha Karn, Wang Jingqiao, Liao Quan, Dai Menghua, Zhang Taiping, Sadula Abuduhaibaier, Lou Wenhui, Yuan Chunhui, Wu Wenming, Zhao Yupei
From the Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences.
Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing.
Pancreas. 2025 Mar 1;54(3):e179-e187. doi: 10.1097/MPA.0000000000002417. Epub 2024 Nov 18.
To evaluate surgical impact on the overall survival (OS) of pancreatic neuroendocrine neoplasm (pNEN) with synchronous hepatic metastases (sHMs).
A total of 163 pNEN-sHM patients were recruited from 3 institutions in China, who were categorized into 3 groups: no resection, resection of the primary lesion, and resection of both primary and hepatic lesions (PHR). Cox regression was employed to evaluate surgical impact on the OS.
In the overall cohort analysis, PHR demonstrated a significant protective effect on OS (hazard ratio, 0.302; 95% confidence interval, 0.127-0.721; P = 0.007). Nevertheless, subgroup analysis revealed PHR conferred a survival advantage in patients with pancreatic neuroendocrine tumor (pNET) located on the pancreatic body/tail (bt-pNET-sHM) (hazard ratio, 0.287; 95% CI, 0.087-0.946; P = 0.040), whereas surgical treatment did not significantly impact survival in the subgroups of pancreatic neuroendocrine carcinoma-sHM or pancreatic head/neck pNET-sHM (hn-pNET-sHM).
In this study, the survival benefit of surgery was observed only in the bt-pNET-sHM subgroup. Considering the multifactorial nature of decision-making, surgical intervention for pNEN-sHM management should be approached with a careful and comprehensive assessment, to prevent excessive surgery strategies.
评估手术对伴有同步肝转移(sHMs)的胰腺神经内分泌肿瘤(pNEN)总生存期(OS)的影响。
从中国3家机构招募了163例pNEN-sHM患者,将其分为3组:未切除组、原发灶切除组和原发灶及肝转移灶切除组(PHR)。采用Cox回归评估手术对OS的影响。
在总体队列分析中,PHR对OS显示出显著的保护作用(风险比,0.302;95%置信区间,0.127 - 0.721;P = 0.007)。然而,亚组分析显示,PHR在位于胰体/胰尾的胰腺神经内分泌肿瘤(pNET)患者(bt-pNET-sHM)中具有生存优势(风险比,0.287;95% CI,0.087 - 0.946;P = 0.040),而手术治疗对胰腺神经内分泌癌-sHM或胰头/颈pNET-sHM(hn-pNET-sHM)亚组的生存没有显著影响。
在本研究中,仅在bt-pNET-sHM亚组中观察到手术的生存获益。考虑到决策的多因素性质,对于pNEN-sHM的管理,手术干预应进行仔细和全面的评估,以避免过度的手术策略。